Tibet Duo Rui Pharmaceutical Co P/B
The P/B (Price-to-Book Ratio) of Tibet Duo Rui Pharmaceutical Co (301075.SZ) as of Oct 23, 2026 is 11.66. In the previous year, P/B (Price-to-Book Ratio) was 9.90 — a change of 17.79% (higher).
Get this data via API
Financial Data API
P/B
11.66
YoY
17.79%
Last updated:
The Tibet Duo Rui Pharmaceutical Co P/B history
3 Years
10 Years
25 Years
Max
| YEAR | P/B | YoY |
|---|---|---|
| 11.66 | +17.79% | |
| 9.90 | +14.09% | |
| 8.68 | -2.66% | |
| 8.92 | +5.51% | |
| 8.45 | -69.43% | |
| 27.64 | -37.96% | |
| 44.56 | -50.64% | |
| 90.27 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Tibet Duo Rui Pharmaceutical Co Stock analysis
Frequently Asked Questions about Tibet Duo Rui Pharmaceutical Co stock
P/B (Price-to-Book Ratio) of Tibet Duo Rui Pharmaceutical Co is 11.66 in 2025.
P/B (Price-to-Book Ratio) of Tibet Duo Rui Pharmaceutical Co changed from 9.90 to 11.66, representing a 17.79% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Tibet Duo Rui Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.
The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.
P/B = Stock Price / Book Value per Share
To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).
A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Tibet Duo Rui Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Valuation — Tibet Duo Rui Pharmaceutical Co
All Key Metrics — Tibet Duo Rui Pharmaceutical Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth